DPP4 and COVID-19: Although the reported effects of DPP‐4 on COVID‐19 patients with diabetes are controversial, these studies mainly focus on the mortality and did not assess the potential effects of DPP‐4 inhibitors on cardiovascular injury in COVID‐19 patients.